| scholarly article | Q13442814 |
| P50 | author | Georg Heinze | Q57012893 |
| P2093 | author name string | Sabine Eichinger | |
| Paul A Kyrle | |||
| P2860 | cites work | Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q27027290 |
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials | Q33910755 | ||
| Risk assessment for recurrent venous thrombosis | Q34153343 | ||
| D-dimer testing to determine the duration of anticoagulation therapy | Q34576728 | ||
| Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
| Prognostic models with competing risks: methods and application to coronary risk prediction | Q37444635 | ||
| Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism | Q37741638 | ||
| PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression | Q41603258 | ||
| Major bleeding complications in a specialized anticoagulation service | Q46648532 | ||
| Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
| The risk of recurrent venous thromboembolism in men and women | Q47332296 | ||
| Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis | Q47351547 | ||
| Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). | Q47923995 | ||
| Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. | Q51574600 | ||
| Cross-validation in survival analysis. | Q54340025 | ||
| Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study | Q56989286 | ||
| Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped | Q57006714 | ||
| Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis | Q57616514 | ||
| D-dimer levels and risk of recurrent venous thromboembolism | Q73864376 | ||
| The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group | Q77909437 | ||
| Apixaban for extended treatment of venous thromboembolism | Q85631280 | ||
| P433 | issue | 1 | |
| P921 | main subject | venous thromboembolism | Q9397786 |
| P304 | page(s) | e000467 | |
| P577 | publication date | 2014-01-02 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model | |
| P478 | volume | 3 |
| Q35878772 | Appropriate use of D-dimer testing can minimize over-utilization of venous duplex ultrasound in a contemporary high-volume hospital |
| Q26796430 | Assessing the risk of recurrent venous thromboembolism--a practical approach |
| Q59827301 | Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative |
| Q36248404 | Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas? |
| Q38429103 | Changing paradigms in the management of deep vein thrombosis. |
| Q52620432 | Coagulation cascade and complement system in systemic lupus erythematosus. |
| Q38561466 | Deep vein thrombosis and pulmonary embolism in the military patient |
| Q45870309 | External validation of the DASH prediction rule: a retrospective cohort study. |
| Q37279270 | Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis |
| Q38980480 | Management of idiopathic venous thromboembolism |
| Q38850540 | Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism |
| Q90259750 | Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study |
| Q92681540 | Risk prediction of recurrent venous thrombosis; where are we now and what can we add? |
| Q36201247 | Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited? |
| Q34525565 | Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. |
| Q52719266 | The Platelet Lifeline to Cancer: Challenges and Opportunities. |
| Q41583955 | The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study |
| Q90691040 | The threshold model revisited |
| Q64108974 | Untapped potential of multicenter studies: a review of cardiovascular risk prediction models revealed inappropriate analyses and wide variation in reporting |
| Q91958762 | Vascular Ultrasound Statement from the Department of Cardiovascular Imaging of the Brazilian Society of Cardiology - 2019 |
| Q26825608 | Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation |
Search more.